fluoropyrimidine, HER2-positive, oxaliplatin, Seagen Inc, tucatinib, Tukysa
Accelerated approval is granted by FDA to tucatinib with trastuzumab for colorectal cancer
In February 2023, the Food and Drug Administration (FDA) sped up the approval of tucatinib (Tukysa, Seagen Inc.) and trastuzumab for the treatment of RAS wild-type HER2-positive colorectal cancer that has spread or can not be rem..